MagicMed Industries Closes Oversubscribed Private Placement of $1,642,880 with Mackie Research Capital Corporation
Calgary-based Magic Med Industries has raised CAD$1,642,880 from the sale of 6,571,520 shares.
Who is Mind Cure Health?
A new functional-and-psychedelic mushroom company is preparing to go public.
Compass Pathways Files For NASDAQ Listing: Psychedelics Game-Changer
A major IPO can be expected to attract a lot of new attention (and capital) to the psychedelic drug industry.
Novamind Appoints Dr. Reid Robison as Chief Medical Officer
Novamind Ventures' new CMO has led over 100 clinical trials and currently serves as a Coordinating Investigator for MAPS.
Champignon to Begin Offering Esketamine Treatment for Adults With Major Depressive Disorder at the Canadian Rapid Treatment Centre of Excellence
Champignon Brands advises that the BCSC has revoked its original cease trade order (June 19, 2020), but a replacement order remains in effect.
Psychedelic Drugs Go Mainstream
As the Renaissance for psychedelic drugs progresses, we see these substances acquiring mainstream status in various ways.
Mydecine Innovations Group Announces Extended Lock-Up Arrangement
Certain large Mydecine shareholders have entered into a voluntary lock-up, covering 52,908,420 common shares.
MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD
MindMed is utilizing MDMA with LSD, to endeavour to reduce side effects of LSD-assisted therapy.
Field Trip Psychedelics Inc. Announces Closing of $11.0 million Financing, Entry into Amalgamation Agreement with Newton Energy Corporation
Field Trip Psychedelics completes its qualifying transaction and definitive agreement with RTO partner.
Why Are Silicon Valley AND Wall Street Backing Psychedelic Drugs?
Wall Street and Silicon Valley investors recently piled into a $30-million psychedelics fund-raising initiative.
Wuhan General Group Corporate Update
Wuhan General (soon to be M2Bio Sciences) has released a corporate update on its psychedelics and cannabis operations.
